Ovarian Serous Adenocarcinoma Clinical Trials

11 recruitingLast updated: June 18, 2026

There are 11 actively recruiting ovarian serous adenocarcinoma clinical trials across 7 countries. Studies span Phase 2, Phase 1, Early Phase 1, Not Applicable, Phase 3. Top locations include Boston, Massachusetts, United States, Houston, Texas, United States, Buffalo, New York, United States. Updated daily from ClinicalTrials.gov.


Ovarian Serous Adenocarcinoma Trials at a Glance

11 actively recruiting trials for ovarian serous adenocarcinoma are listed on ClinicalTrialsFinder across 6 cities in 7 countries. The largest study group is Phase 2 with 5 trials, with the heaviest enrollment activity in Boston, Houston, and Buffalo. Lead sponsors running ovarian serous adenocarcinoma studies include M.D. Anderson Cancer Center, Roswell Park Cancer Institute, and Ohio State University Comprehensive Cancer Center.

Browse ovarian serous adenocarcinoma trials by phase

Treatments under study

About Ovarian Serous Adenocarcinoma Clinical Trials

Looking for clinical trials for Ovarian Serous Adenocarcinoma? There are currently 3 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Ovarian Serous Adenocarcinoma trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Ovarian Serous Adenocarcinoma clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 111 of 11 trials

Recruiting
Phase 2

Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Recurrent Ovarian Cancer

Platinum-Sensitive Ovarian CarcinomaRecurrent Ovarian CarcinomaRecurrent Fallopian Tube Carcinoma+12 more
Roswell Park Cancer Institute80 enrolled2 locationsNCT05231122
Recruiting
Phase 1

This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatment With Toripalimab in Patients With Advanced Solid Tumors

Triple-Negative Breast CancerColorectal, CancerBiliary Tract Cancer+8 more
Zumutor Biologics Inc.100 enrolled3 locationsNCT06451497
Recruiting
Phase 2

APL-2 and Pembrolizumab Versus APL-2, Pembrolizumab and Bevacizumab Versus Bevacizumab Alone for the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer and Malignant Effusion

Recurrent Ovarian CarcinomaRecurrent Fallopian Tube CarcinomaRecurrent Primary Peritoneal Carcinoma+12 more
Roswell Park Cancer Institute60 enrolled1 locationNCT04919629
Recruiting
Phase 3

Minimally Invasive Surgery After Neoadjuvant Chemotherapy for the Treatment of Stage IIIC-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer, LANCE Trial

Stage IV Ovarian Cancer AJCC v8Stage IIIC Ovarian Cancer AJCC v8Advanced Ovarian Carcinoma+22 more
M.D. Anderson Cancer Center580 enrolled19 locationsNCT04575935
Recruiting
Phase 2

Nab-Sirolimus and Endocrine Therapy in Recurrent Low Grade Serous Ovarian Cancer (NARETO)

Low Grade Ovarian Serous Adenocarcinoma
University of Oklahoma37 enrolled1 locationNCT06494150
Recruiting

Data Collection for Patients With Low Grade Ovarian or Peritoneal Tumors

Ovarian CarcinomaPrimary Peritoneal CarcinomaLow Grade Ovarian Serous Adenocarcinoma+3 more
M.D. Anderson Cancer Center2,000 enrolled1 locationNCT00488878
Recruiting
Early Phase 1

Hyperthermic Intraperitoneal Chemotherapy With Cisplatin During Surgery or Cisplatin Before Surgery for the Treatment of Stage III or IV Ovarian, Fallopian Tube or Peritoneal Cancer

Stage III Ovarian Cancer AJCC v8Stage IV Ovarian Cancer AJCC v8Stage IIIA Ovarian Cancer AJCC v8+30 more
Ohio State University Comprehensive Cancer Center45 enrolled1 locationNCT05415709
Recruiting
Phase 1Phase 2

Modi-1 Moditope in Breast, Head and Neck, Ovarian, or Renal Cancer

Triple-Negative Breast CancerSquamous Cell Carcinoma of the Head and NeckRenal Cell Cancer+1 more
Scancell Ltd168 enrolled16 locationsNCT05329532
Recruiting

Developing a Test of Uterine Lavage for the Detection of Ovarian Cancer

Ovarian NeoplasmsStage III Ovarian Cancer AJCC v8Stage IV Ovarian Cancer AJCC v8+12 more
Massachusetts General Hospital250 enrolled6 locationsNCT04794322
Recruiting
Not Applicable

Multi-layer Data to Improve Diagnosis, Predict Therapy Resistance and Suggest Targeted Therapies in HGSOC

High Grade Serous CarcinomaHigh Grade Ovarian Serous Adenocarcinoma
Turku University Hospital200 enrolled1 locationNCT04846933
Recruiting
Phase 2

Alternative Dosing Of Niraparib To Decrease Dose Interruption In First Line Maintenance Treatment For Ovarian Cancer

Ovarian CancerStage III Ovarian CancerStage IV Ovarian Cancer+1 more
Sunnybrook Health Sciences Centre40 enrolled1 locationNCT05961124